Biological check-up

Phase 3Biologic

UUniversity Hospital, Bordeaux

Biological check-up is one of 168 biologic programs targeting Cognitive Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

167

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive DisorderActive, not recruiting

Hemolytic AnemiaActive, not recruiting

StrokeActive, not recruiting

AdenocarcinomaActive, not recruiting

PneumoniaActive, not recruiting

Colorectal CancerActive, not recruiting

Cognitive DisorderPhase 1/Phase 2

Active, not recruiting

Hemolytic AnemiaPhase 2

Active, not recruiting

StrokePreclinical

Active, not recruiting

AdenocarcinomaPhase 3

Active, not recruiting

PneumoniaPreclinical

Active, not recruiting

Colorectal CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

949 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Biological check-up

UUniversity Hospital, Bordeaux

Phase 3

1 2

Eylea

Regeneron

Preclinical

5 3

Emend IV

PORTRAZZA

Gas-X

PPortuguese Oncology Institute, Coimbra

Preclinical

1 6

Ketalar

AAultman Health Foundation

Preclinical

1 7

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 8

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1/2Recruiting

Cognitive Disorder

NCT06776848

Q1 2028

N/ARecruiting

Stroke

NCT06837311

Q3 2028

Phase 2Recruiting

Hemolytic Anemia

NCT05089227

Phase 3Recruiting

Double Diabetes

NCT05305794

Q1 2030

Phase 3Not yet recruiting

Colorectal Cancer

NCT06197425

Clinical

Trials by Indication[1]

Stroke2 trials

Mobile Technologies and Post-stroke Depression

Completed·UUniversity Hospital, Bordeaux·N/A·NCT04043052·401 enrolled

Post-Stroke Secondary Prevention With Digital Monitoring

Recruiting·UUniversity Hospital, Bordeaux·N/A·NCT06837311·388 enrolled

Systemic1 trial

Retinal Microvascularization in OCT-angiography and Systemic Diseases

Recruiting·—··NCT06613555·5,000 enrolled

Age1 trial

The Benefits of Dietary and Micro-nutritional Management for Well-being at Work

Unknown status·LLarena SAS··NCT06137898·200 enrolled

Adenocarcinoma1 trial

PRODIGE 98 : Randomized, Multicenter Phase 3 Trial of Adjuvant Chemotherapy With Modified FOLFIRINOX Versus Capecitabine or Gemcitabine in Patients With Resected Ampullary Adenocarcinoma

Recruiting·—·Phase 3·NCT06813976·294 enrolled

Cognitive Disorder1 trial

A Pilot, Multicentre, Controlled, Open-label Study Evaluating 24 Months of Lithium Carbonate Treatment in Patients With TBR1-related Neurocognitive Disorder

Recruiting·—·Phase 1/2·NCT06776848·12 enrolled

5 more indications

Immunogenicity1 trial

Safety, Immunogenicity And Efficacy Of Vaccination In Military Personnel

Completed·UUniversity of Roma La Sapienza·Phase 4·NCT01807780·262 enrolled

Pneumonia1 trial

Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen

Completed·—··NCT04435223·62 enrolled

Hemolytic Anemia1 trial

Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study

Recruiting·—·Phase 2·NCT05089227·72 enrolled

Colorectal Cancer1 trial

Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal Cancer

Not yet recruiting·—·Phase 3·NCT06197425·1,660 enrolled

Double Diabetes1 trial

Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes"

Recruiting·—·Phase 3·NCT05305794·76 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Biological check-up. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Biological check-up compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Biological check-up. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Bordeaux company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Bordeaux

Biological check-up

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q1 2028

Q3 2028

Q1 2030

Trials by Indication[1]

Stroke2 trials

Systemic1 trial

Age1 trial

Adenocarcinoma1 trial

Cognitive Disorder1 trial

Immunogenicity1 trial

Pneumonia1 trial

Hemolytic Anemia1 trial

Colorectal Cancer1 trial

Double Diabetes1 trial

References

Drug Info

Quick Facts

Related News